Navigation Links
ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis,in Real-World Use of Drug-Eluting Stents

ify patients at highest risk for stent thrombosis. At a minimum, these data reinforce the need for post-implant antiplatelet compliance. Physicians should emphasize to their patients the importance of strict adherence to prescribed antiplatelet therapy and physicians should also consider any new information from the clinical guidelines or the FDA as it becomes available."

ESC and AHA/ACC guidelines recommend a daily anti-platelet regimen for at least one month after bare-metal stent implantation, and six months after TAXUS drug-eluting stent implantation, and ideally up to 12 months in patients who are not at high risk of bleeding. The TAXUS Express Stent Directions For Use (DFU) recommends six months of dual antiplatelet therapy.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.

This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, integration of acquired companies, Boston Scientific's overall business strategy, and other factors described in Boston Scientific's filings with the Securities and Exchange Commission.


     CONTACT:  Paul Donovan

               508-650-8541 (office)

               508-667-5165 (mobile)

               Media Relations

               Boston Scientific Corporation


               Dan Brennan

               508-650-8538 (office)

               617-459-2703 (mobile)

               Investor Relations

 
'"/>




Page: 1 2 3 4 

Related medicine technology :

1. Two-Year Patient Registry Results Support Safety and Efficacy of
Cypher Sirolimus-Eluting Coronary Stent in Real World Uses
2. REACH Registry Demonstrates That Multiple Arterial Disease
Locations Sharply Increase the Risk of Major CV Events in
Outpatients With Atherothrombosis
3. Genetic Analysis Systems Enter the Clinical Mainstream
4. Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing
5. Interim Analysis of Crinone Pregnancy Study to Be Published in
American Society for Reproductive Medicine Journal
6. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking
Hormones, Says New Analysis of Womens Health Initiative Data
7. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery
Calcification, a Predictor of Cardiovascular Events, in Women aged
50-59 taking Estrogen Therapy
8. Haemacure Announces Preliminary Findings of its Plasma Discard
Analysis
9. Further Statistical Analysis of the Recent Phase III trial on Lead
Product M6G Shows Additional Benefits
10. Poniard Pharmaceuticals Announces Promising Data From Interim
Safety Analysis of Phase 1 Combination Trials of Picoplatin in
Colorectal and Prostate Cancers
11. Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to

Bypass Surgery and Better Outcomes Than Bare Metal Stents in

Subgroup Analysis of Diabetic Patients With Multivessel Coronary

Disease
Post Your Comments: